FTC de­mands more in­fo from Bris­tol-My­ers, Cel­gene on pso­ri­a­sis drugs, sig­nal­ing a po­ten­tial hitch for $74B deal

Bris­tol-My­ers Squibb is sig­nal­ing a po­ten­tial hitch in its con­tro­ver­sial $74 bil­lion Cel­gene buy­out — but it’s not the kind that would ap­pear to threat­en the deal it­self.

In an SEC fil­ing the com­pa­ny re­port­ed that the FTC wants to get some ex­tra in­fo on “mar­ket­ed and pipeline prod­ucts for the treat­ment of pso­ri­a­sis,” as it does its an­ti-trust re­view. That will ex­tend their wait­ing pe­ri­od un­til 30 days af­ter they have com­plied with the ex­tra re­quest. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER